Praxis POWER1 Study Misses Primary Endpoint; Pauses POWER2 Enrollment

Praxis Precision Medicines announced that its Phase 2/3 POWER1 study evaluating vormatrigine for focal onset seizures did not meet its primary success measure. However, the study did meet a secondary measure of a 50% response rate, and a more pronounced seizure reduction was observed on the higher 30 mg dose. Vormatrigine was generally well-tolerated with low discontinuation rates, and approximately 90% of patients continued into the open label extension study. Despite these encouraging signals, Praxis is pausing enrollment in the POWER2 study to reassess the vormatrigine program.